Shapely’s enrollment decision is not simply whether a monthly price looks affordable. It is whether the membership, clinical visits, medication order and insurance billing fit together on terms you understand. The company advertises recurring video care, dietitian access and help obtaining medication, including brand-name drugs and self-pay compounded options. But the public documentation does not fully explain how those relationships end, what happens to an unfinished package or which charges continue while an insurance decision is pending.
This documentary review examines Shapely through that contractual lens, using public pages consulted October 19, 2026. The terms identify the business as Zaghi Medical, Inc., doing business as Shapely. Its advertised service area covers adults 18 and older in California, Florida, New York and Texas; nationwide expansion is described as future availability. The central finding is mixed: Shapely provides useful detail about services and several price tiers, but important enrollment and exit questions still need written answers before payment.
At a glance
- Documented availability
- Shapely advertises care for adults 18 and older in California, Florida, New York and Texas.Sources: [6]
- Self-pay membership
- The advertised membership is $99 per month, with a $49 first-month offer. Medication and laboratory testing are separate.Sources: [6]
- Insurance pricing needs reconciliation
- The homepage offers a $9 first membership month with insurance; the UnitedHealthcare page lists $49 monthly plus applicable copays or deductibles, excluding medication.
- Medication packages require membership
- Three-month injectable semaglutide packages start at $99 per month, $297 total; injectable tirzepatide packages start at $166 per month, $498 total. These are specific starter-package prices, not universal monthly rates.
Start with the exit terms, not the introductory offer
The most consequential contract gap is the lack of a documented exit procedure in the material available for review. The consulted terms included an omitted middle section, so they cannot establish a complete cancellation or refund policy. Neither the membership descriptions nor the medication-package pages resolve automatic renewal, required notice, medication returns or early departure from a three-month package. That is a documentation limitation—not evidence that cancellation is impossible or that every payment is nonrefundable.
Before enrolling, ask Shapely to identify the renewal date, cancellation channel and point at which a medication order can no longer be stopped. Request separate answers for membership charges, clinical-visit charges and pharmacy charges. Ending access to the app need not answer what happens to an already authorized prescription or insurance claim. Our guide to cancellation notice and order status explains why those events should be treated as separate checkpoints.
The package duration also needs careful interpretation. A three-month label does not, by itself, establish the quantity dispensed, a minimum membership commitment or an obligation to collect the entire package price upfront. Shapely publishes package totals, but the consulted pages do not clarify collection timing. Ask what happens to any unused portion if the clinician changes the plan, treatment is not tolerated or the patient chooses to leave.
Separate membership, visits and medication on the bill
Shapely’s self-pay membership is advertised at $99 monthly, with $49 for the first month—a $50 introductory reduction. The homepage separately promotes a $9 first membership month when paying with insurance. Neither introductory figure should be treated as the ongoing all-in price. The UnitedHealthcare page supplies another figure: $49 monthly for membership, plus applicable copays or deductibles, with medication excluded. The public pages do not uniformly establish the post-promotion insured rate across plans.
Membership exclusions are unusually important here: both medication and laboratory testing cost extra. Shapely says insured patients may also owe copays, deductibles and coinsurance for care. It describes the continuing membership fee as paying for app access, team chat, education, tracking tools and concierge assistance locating medication. Thus, insurance payment for a visit does not necessarily eliminate the membership charge. Conversely, paying membership does not establish that a prescribed drug is covered.
Shapely’s promise of no surprise bills is a commercial statement, not a substitute for an individual breakdown. Ask for the first charge, subsequent membership rate, expected visit cost-sharing and separate medication price in writing. Include what happens while authorization is pending or a pharmacy has no stock. A written GLP-1 quote is most useful when it identifies each payee and charge rather than combining unlike expenses into one attractive monthly figure.
Read the injectable prices by package and category
The compounded-medication pages advertise injectable semaglutide starting as low as $99 per month and injectable tirzepatide starting as low as $166 per month. Those figures correspond to particular three-month packages, not the ordinary monthly purchase options. Every listed medication option requires an additional membership. The table preserves the provider’s low-mid and high categories as pricing labels, not treatment guidance; a clinician determines what prescription, if any, is appropriate.
The differences extend beyond the first order. Tirzepatide’s three-month starter package costs less than its advertised low-mid refill package, whereas the semaglutide starter and low-mid refill packages share the same listed price. Shapely advertises savings of up to 33% and availability of Affirm and Klarna, but the consulted pages do not explain financing eligibility, interest or repayment terms. Neither financing availability nor a monthly equivalent establishes when Shapely collects the package total.
The semaglutide page states that shipping, syringes and alcohol pads are included in the medication price. That inclusion does not remove the separate membership requirement or laboratory costs. Ask whether the quote identifies the exact preparation and presentation, how the package is supplied and what changes if the prescription changes. The distinction between monthly pricing and payment commitments is particularly relevant when a large package total is displayed beside a smaller monthly equivalent.
| Purchase option | Semaglutide injection | Tirzepatide injection |
|---|---|---|
| Monthly, low-mid category | $139/month | $249/month |
| Monthly, high category | $179/month | $299/month |
| Three-month starter package | $99/month equivalent; $297 total | $166/month equivalent; $498 total |
| Three-month low-mid refill package | $99/month equivalent; $297 total | $199/month equivalent; $597 total |
| Three-month high package | $159/month equivalent; $477 total | $279/month equivalent; $837 total |
What enrollment actually promises to deliver
Shapely describes an intake process that begins with insurance information and health goals, followed by coverage verification before consultation. Patients then connect by video with an assigned clinician who personalizes the plan. The advertised ongoing service includes monthly video visits, prescriptions when appropriate, help with medication coverage and local-pharmacy searches, individual dietitian access, and unlimited support through chat and the app. These are meaningful service descriptions, but they do not specify appointment lead times or support-response deadlines.
The terms explicitly say a prescription is not guaranteed. They also exclude DEA-controlled or scheduled medications and certain other drugs with abuse potential. For people not considered suitable for GLP-1 treatment, Shapely describes alternatives including other medications, lifestyle modification, continuous glucose monitoring and other tools. Paying to enroll therefore buys access to assessment and services, not a contractual entitlement to a particular medicine. The consulted documentation does not provide a complete intake questionnaire or provider-specific clinical eligibility criteria.
Laboratory requirements need confirmation before arranging testing. The homepage strongly recommends recent labs but says they are not required before most weight-loss medications; it accepts results from the six months before enrollment. The Medicare page instead permits results from the previous 12 months. For uninsured patients, Shapely advertises a flat $75 laboratory fee with an in-person Labcorp draw. Ask which recency rule applies to your enrollment route and whether any additional testing would create another charge.
Insurance assistance is not a coverage guarantee
Shapely says it is in network with Medicare and most PPO plans, naming Aetna, Blue Shield and United among examples. These are the company’s representations, not independently verified network findings. Its UnitedHealthcare page correctly makes medication coverage plan-dependent and says prior authorization or proof of medical necessity may be required. Shapely offers to handle prior authorizations, but administrative assistance does not establish approval, a decision deadline or a guaranteed medication price.
The homepage describes commercial-insurance medication copays as typically $25 monthly while warning that some plans require more. That is not an individual quote. Shapely also offers help accessing NovoCare for Wegovy and Lilly Direct for Zepbound, with possible discounts for eligible patients, and expressly disclaims affiliation with Novo Nordisk, Eli Lilly or their patient programs. Its compounded medications, by contrast, are described as self-pay only and not reimbursed by insurance.
There are benefit restrictions beyond drugs. Shapely advertises a cellular-enabled scale for use during the program but says it is unavailable when Aetna or Cigna is the primary insurer. This makes the enrollment benefit list plan-specific rather than universal. Confirm the membership’s included equipment, services and cost-sharing with Shapely, then verify coverage with the insurer. NIDDK likewise distinguishes insurance coverage for weight-management medication from the broader question of accessing clinical care.
Medicare pages need a plan-specific reconciliation
The Medicare page advertises care under a copays-only label, starting as low as $15 monthly or free with secondary insurance. That is a care-pricing statement, not a medication quote. It sits alongside broader language elsewhere requiring membership fees and allowing other cost-sharing. The consulted documentation does not clearly reconcile those descriptions or establish how the homepage’s $9 introductory insured membership offer applies to Medicare patients. A prospective enrollee needs one written explanation specific to their coverage.
The same Medicare page says that, beginning July 1, 2026, eligible Medicare Part D patients can obtain Wegovy, Zepbound and Foundayo for $50 monthly through a Medicare GLP-1 Bridge program. This review did not independently verify that program claim. It must not be read as universal eligibility or immediate access. Meanwhile, the homepage describes Medicare coverage more narrowly, referring to diabetes, cardiovascular disease and obstructive sleep apnea without mentioning Bridge.
These differences are too material to resolve by selecting whichever page offers the lowest number. Ask Shapely which program it proposes to use, what eligibility documentation is required, what the insurer has confirmed and what charges remain if that route is unavailable. Also ask whether membership begins before coverage is resolved. Until those questions are answered, the advertised care copay, membership promotion and claimed medication-program price should remain separate figures rather than an assumed combined offer.
Locate responsibility across the platform, clinician and pharmacy
Shapely’s terms contain an unresolved description of the clinical relationship. One passage refers to clinicians employed or contracted by Shapely; another says Shapely does not employ, supervise or control the clinicians providing care and is not responsible for its quality or appropriateness. This review cannot settle that inconsistency. Before enrollment, ask which entity provides the medical service, which clinician manages follow-up and where complaints about clinical care versus billing should be directed.
The terms allow patients receiving a prescription to request transmission to a pharmacy of their choice. Separately, Shapely says it works exclusively with what it describes as reputable, state-licensed 503A and 503B compounding pharmacies. The consulted pages do not name those pharmacies or provide their licenses. Ask which pharmacy would dispense the specific order and whether choosing another pharmacy changes package pricing, included supplies or shipping arrangements. The pharmacy-choice language alone does not answer those commercial questions.
Both injectable pages advertise free two-day shipping, but neither establishes the full interval from enrollment through evaluation, prescribing, preparation and delivery. Refrigeration arrangements, tracking, lost-package handling and damage remedies are not specified in the consulted material. FDA advises not using an injectable GLP-1 product that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. Mapping platform, clinician and pharmacy responsibilities before ordering makes that escalation route clearer.
Keep product descriptions and support promises in perspective
Shapely’s catalog lists Oral Wegovy, Ozempic and Wegovy as semaglutide products, and Zepbound and Mounjaro as tirzepatide products. It also lists Foundayo as orforglipron and Contrave as bupropion and naltrexone. These are descriptions of its advertised catalog, not independent confirmation of every product’s regulatory status or individual coverage. An insurance-accepted label does not establish that a particular patient can obtain that product through their plan.
For compounded options, Shapely describes prescriptions customized to an individual clinical evaluation, potentially involving formulations or strengths not commercially available. It acknowledges that compounded preparations are not FDA approved. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence, but neither Shapely’s pharmacy assurances nor its service contract establishes equivalence or provider-specific clinical outcomes.
Communication also has boundaries worth understanding. Unlimited app and chat support does not establish a guaranteed response time, and the terms warn that texts and emails may be unencrypted and intercepted. Ask which channel is intended for sensitive information and urgent treatment concerns. Finally, the homepage discloses that customer testimonials were shared with permission and compensated for usage rights, with results varying. Those marketing accounts do not resolve contractual obligations or predict an individual patient’s experience.
Questions & answers
Does Shapely’s $49 self-pay offer include medication?
No. The $49 offer is the first month of a self-pay membership advertised at $99 monthly thereafter. Medication and labs are excluded. The injectable medication pages require membership in addition to their listed medication prices. Ask for separate membership, medication and laboratory line items, rather than treating the introductory membership charge as the full cost of starting treatment.
Can I cancel a Shapely three-month package and get the balance back?
The consulted documentation does not answer that question. It does not establish an early-exit refund, a medication-return policy or the collection schedule for package totals. Request the applicable package agreement before paying, including what happens after a prescription change or intolerance. Permission to cancel future services, if offered, would not by itself establish a refund for medication already ordered.
Will Shapely accept laboratory results I already have?
Its pages give different windows. The homepage accepts labs completed within six months before enrollment, while the Medicare page says 12 months. The homepage strongly recommends recent testing but does not require it before most weight-loss medicines. Confirm the rule for your care plan before arranging another draw. Uninsured laboratory testing is advertised at $75 through an in-person Labcorp visit.
Can I use my own pharmacy?
Shapely’s terms say that, if you receive a prescription, you may instruct Shapely or the clinician to send it to your chosen pharmacy. That does not establish that every pharmacy can fill every preparation or honor Shapely’s advertised package price. Confirm availability, payment arrangements, included supplies and any effect on shipping before asking for the prescription to be transferred.
Does Shapely guarantee a prescription or insurance approval?
No prescription is guaranteed under its terms. Shapely offers coverage verification and prior-authorization assistance, but its UnitedHealthcare page makes drug coverage dependent on the individual plan and possible medical-necessity requirements. Ask whether membership charges begin before those decisions and what services remain available if the requested medicine is not prescribed or covered.
How quickly does Shapely deliver medication?
The injectable semaglutide and tirzepatide pages advertise free two-day shipping. They do not establish delivery two days after enrollment or specify the time needed for consultation, authorization, preparation or prescription processing. Ask for an order-specific timeline and the pharmacy’s delivery-problem procedure. FDA advises against using injectable GLP-1 medication that arrives warm or inadequately refrigerated; contact the provider or dispensing pharmacy.
Our assessment
Shapely documents a substantive care offering: recurring video visits, dietitian access, app support, insurance assistance and multiple medication pathways. Its published medication tables also provide more detail than a single starting price. The contractual weakness is the incomplete connection between those offerings and the rules governing continued billing, cancellation, package changes and refunds. Conflicting descriptions of Medicare pricing, laboratory recency and clinician relationships add questions that should be resolved individually. For an adult in one of its four advertised states, the useful next step is not to assume the lowest advertised figure applies. Obtain the complete current agreement, a plan-specific written quote, the dispensing pharmacy’s identity and clear exit instructions before authorizing payment. Those answers would make the documented service easier to evaluate without treating marketing assurances as binding clarity.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Shapely — weightloss/insurance/unitedhealthcare ↗
- Shapely — weightloss/medications/semaglutide ↗
- Shapely — terms of use ↗
- Shapely — official website ↗
- Shapely — weightloss/insurance/medicare ↗
- Shapely — weightloss/medications/tirzepatide ↗